Full Answer
Check pen label before each use to make sure it is your 10 mcg BYETTA Pen. Pull off blue pen cap. Check BYETTA in the cartridge. The liquid should be clear, colorless, and free of particles. If not, do not use. A small air bubble in the cartridge is normal. Remove paper tab from outer needle shield. Push capped needle straight onto pen.
For further information call emc accessibility on 0800 198 5000. The product code (s) for this leaflet is: PLGB 17901/0316 . Byetta 5 micrograms solution for injection, prefilled pen.
Check BYETTA in the cartridge. The liquid should be clear, colorless, and free of particles. If not, do not use. A small air bubble in the cartridge is normal.
Pull off blue pen cap and check BYETTA in the cartridge. The liquid should be clear, colorless, and free of particles. If not, do not use. A small air bubble will not harm you or affect your dose. ready to pull dose knob out ready to turn to dose position ready to inject 5 mcg dose knob in and ready to reset BYETTA Liquid Dose Window Symbols
Rheumatoid arthritis with rheumatoid factorICD-10 code M05 for Rheumatoid arthritis with rheumatoid factor is a medical classification as listed by WHO under the range - Arthropathies .
Encounter for other specified aftercareICD-10 code Z51. 89 for Encounter for other specified aftercare is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
The ICD-10 code Z79. 4 (long-term, current, insulin use) should be clearly documented and coded if applicable.
ICD-10 code R06. 09 for Other forms of dyspnea is a medical classification as listed by WHO under the range - Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified .
ICD-10 code Z51. 11 for Encounter for antineoplastic chemotherapy is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
Use Z codes to code for surgical aftercare. Z47. 89, Encounter for other orthopedic aftercare, and. Z47. 1, Aftercare following joint replacement surgery.
The ICD-10 section that covers long-term drug therapy is Z79, with many subsections and specific diagnosis codes.
The incorrect portion of the response came as an aside at the end, where it was stated that “it would be redundant to assign codes for both diabetic nephropathy (E11. 21) and diabetic chronic kidney disease (E11. 22), as diabetic chronic kidney disease is a more specific condition.” It is true you wouldn't code both.
ICD-10 Code for Type 2 diabetes mellitus with other circulatory complications- E11. 59- Codify by AAPC.
ICD-10 Code for Atherosclerotic heart disease of native coronary artery without angina pectoris- I25. 10- Codify by AAPC.
ICD-9 Code Transition: 780.79 Code R53. 83 is the diagnosis code used for Other Fatigue. It is a condition marked by drowsiness and an unusual lack of energy and mental alertness. It can be caused by many things, including illness, injury, or drugs.
ICD-10 code M62. 81 for Muscle weakness (generalized) is a medical classification as listed by WHO under the range - Soft tissue disorders .
Becton, Dickinson and Company needles are suitable to use with the Byetta pen. Injection needles are not included.
You should inject this medicine under the skin (subcutane ous injection) of your upper leg (thigh), stomach area (abdomen), or upper arm. If you are using Byetta and an insulin you must make two separate injections.
You have diabetes because your body does not make enough insulin to control the level of sugar in your blood or if your body is not able to use the insulin properly. The medicine in Byetta helps your body to increase the production of insulin when your blood sugar is high.
It is an injectable medicine used to improve blood sugar control in adults with type 2 (non-insulin dependent) diabetes mellitus.
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.
If you have ever had inflammation of the pancreas (pancreatitis) (see section 4).
liraglutide and prolonged-release exenatide), as taking these medicines with Byetta is not recommended .
What is it? What is it used for? How is it used? How does it work? How has it been studied? What benefits has it shown during the studies? What is the risk associated? Why has it been approved?
Byetta is a solution for injection that contains the active substance exenatide. It is available as prefilled injection pens that provide either 5 or 10 micrograms of exenatide in each dose.
Byetta is used to treat type 2 diabetes. It is used together with other antidiabetes medicines in patients whose blood glucose (sugar) levels are not adequately controlled with the maximum tolerated doses of the other medicines.
Byetta is given by injection under the skin of the thigh, the abdomen (tummy) or the upper arm, using the injection pen. The pen has a user manual.
Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively. The active substance in Byetta, exenatide, is an ?incretin mimetic?.
Byetta has been studied in seven main studies involving a total of almost 3,000 patients whose blood glucose was not adequately controlled with other antidiabetes medicines.
Byetta was more effective than placebo in reducing the levels of HbA1c when used in combination with other antidiabetes medicines. When it was added to metformin and/or sulphonylureas, the 5-microgram dose of Byetta decreased HbA1c levels by an average of 0.59% after 30 weeks, and the 10-microgram dose decreased them by an average of 0.89%.
Byetta 10 mcg Prefilled Pen is used along with diet and exercise to control blood sugar levels in adults with type 2 diabetes mellitus. This medicine is normally used in patients who have not achieved adequate control of blood sugar levels with other oral therapies. It is not used to treat type 1 diabetes mellitus. It should also not be used in place of insulin.
Byetta 10 mcg Prefilled Pen may interact with many other medicines and may cause severe adverse effects. Hence, it is advised that you inform the doctor about all your current medicines including any herbs and supplements before beginning treatment with this medicine.
Byetta is indicated for treatment of type 2 diabetes mellitus in combination with:
Byetta is for use by one person only.
Immediate-release exenatide is available as either a 5 mcg or a 10 mcg exenatide per dose pre-filled pen.
Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that exhibits several antihyperglycaemic actions of glucagon-like peptide-1 (GLP-1). The amino acid sequence of exenatide partially overlaps that of human GLP-1. Exenatide has been shown to bind to and activate the known human GLP-1 receptor in vitro, its mechanism of action mediated by cyclic AMP and/or other intracellular signalling pathways.
Nonclinical studies have shown that exenatide is predominantly eliminated by glomerular filtration with subsequent proteolytic degradation. In clinical studies the mean apparent clearance of exenatide is 9 L/h and the mean terminal half-life is 2.4 h. These pharmacokinetic characteristics of exenatide are independent of the dose.
The most frequent adverse reactions were mainly gastrointestinal related (nausea, vomiting and diarrhoea). The most frequently reported single adverse reaction was nausea which was associated with the initiation of treatment and decreased over time. Patients may experience hypoglycaemia when immediate-release exenatide is used with a sulphonylurea. Most adverse reactions associated with immediate-release exenatide were mild to moderate in intensity.
The effect of immediate-release exenatide to slow gastric emptying may reduce the extent and rate of absorption of orally administered medicinal products. Patients receiving medicinal products of either a narrow therapeutic ratio or medicinal products that require careful clinical monitoring should be followed closely. These medicinal products should be taken in a standardised way in relation to immediate-release exenatide injection. If such medicinal products are to be administered with food, patients should be advised to, if possible, take them with a meal when immediate-release exenatide is not administered.
What is it and how is it used? What do you have to consider before using it? How is it used? What are possible side effects? How should it be stored? Further information
BYETTA is an injectable medicine used to improve blood sugar control in adults with type 2 (non insulin dependent) diabetes mellitus.
If you are allergic (hypersensitive) to exenatide or any of the other ingredients of BYETTA, listed at the end of this leaflet.
Always use BYETTA exactly as your doctor or diabetes nurse has told you. You should check with your doctor, diabetes nurse or pharmacist if you are unsure.
Like all medicines, BYETTA can have side effects although not everybody gets them.
Byetta is not approved for use by anyone younger than 18 years old.
Byetta is injected under the skin. A healthcare provider may teach you how to properly use the medication by yourself.
Byetta is a short-acting form of exenatide. Byetta is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes.
Do not use after eating a meal. You must use Byetta within 60 minutes (1 hour) before eating. Your injections should be given at least 6 hours apart. You may have low blood sugar (hypoglycemia) and feel very hungry, dizzy, irritable, confused, anxious, or shaky.
Get emergency medical help if you have signs of an allergic reaction to Byetta: hives, itching; rapid heartbeats; difficult breathing; feeling light-headed; swelling of your face, lips, tongue, or throat.
Byetta is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes. Byetta is not for treating type 1 diabetes.
Stop using this medicine and call your doctor at once if you have nausea and vomiting with severe pain in your upper stomach spreading to your back. You should not use Byetta together with fast-acting or short-acting insulins. Do not use this medicine together with Bydureon.